Rare Histological Variants of Liver Cancer and Their Management: A Single-Institution Experience.
Journal
Case reports in hepatology
ISSN: 2090-6587
Titre abrégé: Case Reports Hepatol
Pays: United States
ID NLM: 101622103
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
12
2020
revised:
23
03
2021
accepted:
15
04
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Primary liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma, are a major cause of cancer-related morbidity and mortality worldwide. There are several histologically and biologically distinct subtypes of liver cancer that have previously been reported. However, literature regarding the nonsurgical management of these patients upon disease recurrence remains limited. These variants include combined HCC-cholangiocarcinoma (cHCC-CC), Epstein-Barr virus- (EBV-) associated carcinoma, undifferentiated carcinoma, and clear cell or thyroid-like variants of HCC. Here, we aim to highlight the pathologic features, clinical course, and outcomes of five patients with these unusual hepatic tumors and explain the rationale behind the choice of their systemic therapies upon disease recurrence. All patients underwent surgical resection as the standard of care for localized disease, and upon relapse, they were treated with either chemotherapy, targeted therapy, immunotherapy, or active surveillance based on the clinical context and tumor histology. These rare variants are important to recognize as they have prognostic and therapeutic implications, and there are currently insufficient data in the literature to guide further therapy.
Identifiants
pubmed: 33968454
doi: 10.1155/2021/6654229
pmc: PMC8081640
doi:
Types de publication
Case Reports
Langues
eng
Pagination
6654229Informations de copyright
Copyright © 2021 Brandon Swed et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Ann Hepatol. 2012 Nov-Dec;11(6):961-5
pubmed: 23109464
J Cancer Res Ther. 2015 Jul-Sep;11(3):656
pubmed: 26458650
Histopathology. 2014 Nov;65(5):674-83
pubmed: 24804938
Surg Case Rep. 2017 Dec;3(1):12
pubmed: 28074442
Clin J Gastroenterol. 2019 Apr;12(2):128-134
pubmed: 30374884
J Gastrointest Cancer. 2017 Jun;48(2):211-216
pubmed: 27194053
Ann Hepatobiliary Pancreat Surg. 2020 May 31;24(2):182-187
pubmed: 32457264
Jpn J Clin Oncol. 1998 Jun;28(6):401-4
pubmed: 9730157
Virchows Arch. 2010 Mar;456(3):339-42
pubmed: 20082203
Diagn Mol Pathol. 2004 Sep;13(3):183-9
pubmed: 15322431
Ann Hepatol. 2014 May-Jun;13(3):317-22
pubmed: 24756005
Pathologica. 1994 Jun;86(3):307-10
pubmed: 7808805
Dig Dis Sci. 2013 Jul;58(7):2114-23
pubmed: 23397471
J Hepatocell Carcinoma. 2018 Dec 28;6:11-21
pubmed: 30643759
Int J Surg Pathol. 2018 Oct;26(7):649-654
pubmed: 29665738
World J Gastroenterol. 2010 May 28;16(20):2571-6
pubmed: 20503460
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Internist (Berl). 2020 Feb;61(2):164-169
pubmed: 31919533
World J Gastroenterol. 2015 Apr 7;21(13):4089-95
pubmed: 25852298
Int J Surg Case Rep. 2018;51:45-49
pubmed: 30142599
Am J Surg Pathol. 2001 Jul;25(7):956-60
pubmed: 11420469